A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045) "ACT V"


Phase 3 Results N/A

Summary of Purpose

The purpose of this study is to evaluate the safety and efficacy of vernakalant injection in subjects with recent onset (AF > 3 hours to <= 7 days), symptomatic atrial fibrillation and no evidence or history of congestive heart failure.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 6 February 2014.

1 Oct 2009 1 Oct 2009 1 Nov 2010 1 Nov 2010 1 Feb 2014 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


  • Astellas Pharma Global Development Phone: 800-888-7704 ext 5473 Email: clintrials.info@us.astellas.com